A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder ...
Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.
PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...
Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results